Medpace Holdings, Inc. $MEDP Shares Acquired by OMERS ADMINISTRATION Corp

Key Points

• OMERS ADMINISTRATION Corp increased its stake in Medpace Holdings, Inc. by 39.6%, resulting in ownership of 6,074 shares worth approximately $1.85 million.
• In related transactions, Medpace insiders, including VP Susan E. Burwig and CEO August J. Troendle, sold significant shares on July 28th, reflecting a decrease in their own holdings.
• Medpace reported a net margin of 18.74% and a significant revenue increase of 14.2% year-over-year, with earnings per share of $3.10 for the last quarter.

OMERS ADMINISTRATION Corp raised its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 39.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,074 shares of the company's stock after purchasing an additional 1,724 shares during the period. OMERS ADMINISTRATION Corp's holdings in Medpace were worth $1,851,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of MEDP. Mawer Investment Management Ltd. purchased a new stake in shares of Medpace in the 1st quarter valued at approximately $212,131,000. Vulcan Value Partners LLC increased its position in shares of Medpace by 221.6% in the 1st quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company's stock valued at $99,159,000 after purchasing an additional 224,578 shares during the last quarter. Fundsmith LLP purchased a new stake in shares of Medpace in the 4th quarter valued at approximately $42,372,000. Spyglass Capital Management LLC boosted its holdings in shares of Medpace by 85.1% in the 4th quarter. Spyglass Capital Management LLC now owns 262,660 shares of the company's stock valued at $87,264,000 after buying an additional 120,778 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Medpace by 9.4% in the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company's stock valued at $361,596,000 after buying an additional 102,015 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Stock Down 0.6%

Shares of MEDP traded down $2.67 during mid-day trading on Thursday, hitting $478.57. The company had a trading volume of 158,951 shares, compared to its average volume of 445,656. The business's 50-day simple moving average is $405.65 and its 200-day simple moving average is $342.20. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $501.30. The stock has a market cap of $13.44 billion, a PE ratio of 35.58, a P/E/G ratio of 2.99 and a beta of 1.44.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. The firm had revenue of $603.31 million for the quarter, compared to analysts' expectations of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. Medpace's revenue was up 14.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. TD Cowen restated a "sell" rating and set a $366.00 price objective (up previously from $283.00) on shares of Medpace in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. UBS Group downgraded shares of Medpace from a "neutral" rating to a "sell" rating and upped their price objective for the stock from $300.00 to $305.00 in a research report on Tuesday, July 29th. Rothschild Redb downgraded shares of Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday. Finally, Cowen downgraded shares of Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the company's stock. According to data from MarketBeat, Medpace presently has an average rating of "Reduce" and an average target price of $412.73.

Insider Activity

In other news, President Jesse J. Geiger sold 41,801 shares of Medpace stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $453.11, for a total transaction of $18,940,451.11. Following the sale, the president owned 36,503 shares in the company, valued at $16,539,874.33. This trade represents a 53.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Susan E. Burwig sold 7,500 shares of Medpace stock in a transaction on Monday, July 28th. The stock was sold at an average price of $450.14, for a total transaction of $3,376,050.00. Following the completion of the sale, the vice president owned 57,500 shares of the company's stock, valued at approximately $25,883,050. This trade represents a 11.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 151,266 shares of company stock valued at $69,311,427 over the last quarter. 20.30% of the stock is owned by insiders.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.